Bisphosphonates and denosumab vs Teriparatide
How to tell Bisphosphonates and denosumab and Teriparatide apart when a board question makes them look alike.
Bisphosphonates/denosumab reduce osteoclast resorption; teriparatide builds bone through intermittent PTH signaling.
Side by side
Antiresorptive therapy: bisphosphonates impair osteoclasts from bone surface; denosumab blocks RANKL and has rebound fracture risk if stopped abruptly.
Anabolic intermittent PTH analog for severe osteoporosis, with hypercalcemia and skeletal malignancy precautions.
Bisphosphonates bind hydroxyapatite and inhibit osteoclast-mediated resorption; denosumab prevents RANKL-driven osteoclast activation.
Intermittent teriparatide stimulates osteoblast activity more than osteoclast activity, building bone.
Alendronate upright/esophagitis points bisphosphonate; RANKL antibody plus hypocalcemia/rebound risk points denosumab.
Daily PTH analog injection, hypercalcemia, or avoidance in Paget/radiation/skeletal malignancy risk points teriparatide.
The trap
PTH can resorb or build bone depending on exposure pattern; intermittent dosing is the anabolic clue.
The repair move
Separate osteoporosis drugs into antiresorptive versus anabolic before thinking about side effects.
Try a free question
CoreA patient with osteoporosis is told to take alendronate with water and remain upright to reduce esophagitis. Rare jaw osteonecrosis and atypical femur fracture risks are reviewed. Which class is this?
Show answer and explanation
Answer: A. Bisphosphonate. Bisphosphonates bind bone mineral and impair osteoclast-mediated resorption; esophagitis, jaw osteonecrosis, and atypical femur fracture are key clues.
Why the other choices are tempting
- B. Denosumab is a RANKL antibody with hypocalcemia and rebound fracture concerns after stopping.
- C. Teriparatide is intermittent PTH analog anabolic therapy.
- D. Calcitonin is less potent and not the upright/esophagitis clue.
- E. Raloxifene is a SERM.
Flashcards
Tap a card to flip it.
What is the fastest separator for Bisphosphonates and denosumab vs Teriparatide?
Bisphosphonates/denosumab reduce osteoclast resorption; teriparatide builds bone through intermittent PTH signaling.
What clue should make you choose Bisphosphonates and denosumab?
Antiresorptive therapy: bisphosphonates impair osteoclasts from bone surface; denosumab blocks RANKL and has rebound fracture risk if stopped abruptly.
Quick answers
What is the fastest way to tell Bisphosphonates and denosumab from Teriparatide?
Bisphosphonates/denosumab reduce osteoclast resorption; teriparatide builds bone through intermittent PTH signaling.
What is the key clue for Bisphosphonates and denosumab?
Antiresorptive therapy: bisphosphonates impair osteoclasts from bone surface; denosumab blocks RANKL and has rebound fracture risk if stopped abruptly.
What is the key clue for Teriparatide?
Anabolic intermittent PTH analog for severe osteoporosis, with hypercalcemia and skeletal malignancy precautions.
What is the common trap with Bisphosphonates and denosumab vs Teriparatide?
PTH can resorb or build bone depending on exposure pattern; intermittent dosing is the anabolic clue.